Abbott Laboratories ABT

The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, registering a 10.5% CAGR. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digital pathology and multi-omics technologies. Predictive biomarkers led the efficacy segment in 2025, while immunoassays held the largest technology share. Asia Pacific is forecast to be the fastest-growing region. Key players include Roche, Abbott, Thermo Fisher Scientific, Q

The global disposable medical device sensors market is projected to grow from USD 11.86 billion in 2026 to USD 16.13 billion by 2031, registering a 6.4% CAGR. Growth is driven by chronic and infectious diseases, remote patient monitoring, point-of-care diagnostics, wearable devices, home healthcare, and infection-prevention needs. Biosensors currently lead the market, while strip sensors are expected to gain the largest share. The US will record North America’s highest CAGR. Key players include

Lazada, a leading eCommerce platform in Southeast Asia, celebrated the achievements of its 170,000-strong brand ecosystem at the annual LazMall Brand Gala 2026, as more brands reached major sales milestones on the platform.

Abbott Laboratories (ABT) expanded its presence in cancer screening with the launch of SimpleScreen CRC in the US. The test is an FDA-approved blood-based option for average-risk adults who decline traditional colorectal screening methods. Against that product backdrop, Abbott Laboratories has seen its 1 month share price return fall about 10.2%, while the 90 day share price return is up 9.5%. This points to fading short term momentum compared with a still positive multi quarter trend. Recent...

Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.

Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.

Abbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at average risk for the disease. Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus® test in Abbott's colorectal cancer screening portfolio, providing another way to help reach people who otherwise may remain unscreened.

BBNX's Eversense 365 partnership is likely to broaden CGM choice and strengthen its automated insulin delivery ecosystem across iLet and mint.

Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One has raised its dividend for 54 consecutive years and still trades at a rare discount.

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Growth is driven by rising cardiovascular disease, telehealth adoption, and advances in wearable ECG devices, implantable monitors, AI analytics, and cloud platforms. North America leads, while Asia-Pacific is expected to grow fastest.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Remote Cardiac Monitoring Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.The global Remote Cardiac Monitoring Mark

Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably more diversification across medical devices, diagnostics, nutrition and established pharmaceuticals, as […]

Grail stock rises after a FDA advisory panel recommends approval of the biotech’s cancer blood test.

Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]